The Institute for Clinical and Economic Review’s president, Steven Pearson, says Gilead’s decision to price its COVID-19 treatment remdesivir at $3,120 was a “responsible pricing decision based on the evidence we have today.”
Gilead also plans to offer some federal programs a discounted price of about $2,340.
“The price is largely in line with ICER’s independent assessment suggesting that a price of approximately $2,800 would be reasonable in proportion to the added benefits for patients and the cost offsets in the health system now that dexamethasone is rapidly becoming standard of care,” Pearson said in a statement.
To read Pearson’s full response on ICER’s website, click here.
